CD105, esVEGR2 and MYC three-protein combined prediction esophageal squamous carcinoma patient prognosis kit
A technology of esophageal squamous cell carcinoma and a kit, which can be applied to measurement devices, instruments, scientific instruments, etc., can solve the problem of not predicting the prognosis of patients with esophageal squamous cell carcinoma.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0013] We collected archival wax blocks of surgical specimens from 124 patients with esophageal squamous cell carcinoma from 2000 to 2006. Further detailed description will be given below in conjunction with the embodiments of the accompanying drawings.
[0014] The steps of immunohistochemical hypersensitivity two-step method are as follows:
[0015] After the specimens were serially sectioned, dewaxed with xylene, and hydrated with graded alcohol, the expression of the target protein was detected by an ultrasensitive two-step method. The specific method is as follows:
[0016] (1) The slices were repaired with 0.01M citrate repair solution, 3% H 2 o 2 After inactivating endogenous peroxidase and blocking with goat serum, incubate with CD105, esVEGFR2 and MYC antibodies overnight at 4°C;
[0017] (2) After the slices were incubated with Polymer enhancer and Polymer polymer respectively, DAB color development;
[0018] (3) The sections were counterstained with hematoxylin...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com